Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy O Johnson-Levonas

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Lipids in Health and Disease|November 18, 2011
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatinMichel Farnier, Qian Dong, Arvind Shah, et al.
Vascular Health and Risk Management|May 24, 2014
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemiaMichel Farnier, Erluo Chen, Amy O Johnson-Levonas, et al.
Clinical Therapeutics|December 26, 2007
Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniquesLeiv Ose, Robert Reyes, Amy O Johnson-Levonas, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|January 12, 2010
Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosteroneSteven A Kaplan, Jianxin Lin, Amy O Johnson-Levonas, et al.
Journal of Clinical Lipidology|June 5, 2012
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemiaChristie Ballantyne, Gilbert Gleim, Nancy Liu, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|December 17, 2009
Elevated high sensitivity C-reactive protein levels in aging men with low testosteroneSteven A Kaplan, Amy O Johnson-Levonas, Jianxin Lin, et al.
Journal of Clinical Lipidology|February 12, 2015
Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatinRonald M Krauss, Cathy Anne Pinto, Yang Liu, et al.
Atherosclerosis|July 25, 2013
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemiaMichel Farnier, John R Guyton, Erin Jensen, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler deviceTeddy Kosoglou, James Hubbell, Amy O Johnson-Levonas, et al.
Journal of Clinical Pharmacology|September 29, 2009
Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarinD Hamish Wright, Gary A Herman, Andrea Maes, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Lipids in Health and Disease|November 18, 2011
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatinMichel Farnier, Qian Dong, Arvind Shah, et al.
Vascular Health and Risk Management|May 24, 2014
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemiaMichel Farnier, Erluo Chen, Amy O Johnson-Levonas, et al.
Clinical Therapeutics|December 26, 2007
Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniquesLeiv Ose, Robert Reyes, Amy O Johnson-Levonas, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|January 12, 2010
Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosteroneSteven A Kaplan, Jianxin Lin, Amy O Johnson-Levonas, et al.
Journal of Clinical Lipidology|June 5, 2012
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemiaChristie Ballantyne, Gilbert Gleim, Nancy Liu, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|December 17, 2009
Elevated high sensitivity C-reactive protein levels in aging men with low testosteroneSteven A Kaplan, Amy O Johnson-Levonas, Jianxin Lin, et al.
Journal of Clinical Lipidology|February 12, 2015
Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatinRonald M Krauss, Cathy Anne Pinto, Yang Liu, et al.
Atherosclerosis|July 25, 2013
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemiaMichel Farnier, John R Guyton, Erin Jensen, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler deviceTeddy Kosoglou, James Hubbell, Amy O Johnson-Levonas, et al.
Journal of Clinical Pharmacology|September 29, 2009
Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarinD Hamish Wright, Gary A Herman, Andrea Maes, et al.
Pageof 8